DOJ may cost Aegerion patients

Share this article:

Aegerion has put investors on alert that the Department of Justice investigation into its Juxtapid marketing may be a considerable weight on the drugmaker's financials.

Forbes highlighted the signal paragraph in the company's annual report Wednesday, in which the company addressed both the DOJ investigation and a Warning Letter it received from the FDA's bad-ad unit, OPDP. Resolving OPDP's complaints appears to be the easier of the two tasks—the company said it will run a corrective ad on CNBC.

This televised effort is penance for comments Aegerion's CEO made during two interviews in which the watchdog said the executive talked about drug benefits the company had no right to claim.

The DOJ took note of the company and subpoenaed marketing information in January. This is going to require more than a video shoot, and the company noted in its annual report that it plans “to vigorously defend ourselves,” but that this effort may be costly in terms of court fees and market impact.

“This investigation could adversely impact our reputation and the willingness of physicians to prescribe lomitapide for their HoFH patients,” the company said in its annual report.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.